Therma Bright's International Patent Application for TherOZap(TM) Enters National Phases in the US, Europe & Canada
Toronto, Ontario--(Newsfile Corp. - September 5, 2019) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, today announces that the TherOZap™ technology under the Company's former name, The Jenex Corporation, has filed an international patent application under the PCT convention for its thermal therapy TherOZap™ and has recently entered the national phases in the US, Europe and Canada. In the international phase, the international search report found all searched claims to be novel. In the national phases, the claims will be further examined for patentability and allowance is expected. Therma is in the process of changing the international patent application name to: Therma Bright Inc. from the former name, The Jenex Corporation.
Rob Fia, CEO, commented:
"Further to our press release on September 4rd, 2019 highlighting that our TherOZap™ technology proves successful at inhibiting the Zika virus during in-vitro tests, we are pleased to announce that Therma is strengthening its intellectual property portfolio.
Our Company has come up with novel ideas on how to potentially combat mosquito borne diseases using advanced technology. The fact that the international search report found all searched claims to be novel, confirms that Therma is on the right track and we intend to protect our TherOZap™ intellectual property and other ideas for the benefit of Therma shareholders."
About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological and healthcare needs. Clear and healthy skin for all is at the core of the Company's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.
Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). The Company received approval for the above claims from FDA (United States) in 1997.
For further information please contact:
Therma Bright Inc.
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events or the Company's future performance and include future patents for the Company's TherOZap™ technology against the Zika virus and potentially other mosquito borne diseases and other ideas, all as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company may not protect all or any of the patents as described in this news on the timelines described. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47547